首站-论文投稿智能助手
典型文献
Enhanced trimeric ACE2 exhibits potent prophylactic and therapeutic efficacy against the SARS-CoV-2 Delta and Omicron variants in vivo
文献摘要:
Dear Editor, The outbreak of coronavirus disease 2019(COVID-19)has resulted in a severe global pandemic that has lasted for more than two years.1 Several vaccines were developed at an unprecedented speed to protect billions of people.2 Many monoclonal antibodies have also been discovered,several of which are in the clinical stages.3 However,limited vaccine availability and vaccine hesi-tancy compromise the impact of vaccines.The continuous evolution of SARS-CoV-2 has also resulted in many variants that can escape immunity,reducing the effects of vaccines and antibodies.4 With more than 30 mutations in the spike protein,the Omicron variant escapes the majority of existing antibodies and extensively evades vaccine-induced immunity.56 Thus,therapeu-tics that are broadly effective against current and future emerging SARS-CoV-2 variants are still highly desirable.
文献关键词:
作者姓名:
Mengjiao Li;Zi-Wei Ye;Kaiming Tang;Liang Guo;Wenwen Bi;Yuyuan Zhang;Yan-dong Tang;Guoguang Rong;Mohamad Sawan;Xin Yin;Ren Sun;Shuofeng Yuan;Bobo Dang
作者机构:
Fudan University,Shanghai,China;Key Laboratory of Structural Biology of Zhejiang Province,School of Life Sciences,Westlake University,Hangzhou,Zhejiang,China;Center for Infectious Disease Research,Westlake Laboratory of Life Sciences and Biomedicine,Hangzhou,Zhejiang,China;Institute of Biology,Westlake Institute for Advanced Study,Hangzhou,Zhejiang,China;Department of Microbiology,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Pokfulam,Hong Kong,China;State Key Laboratory of Emerging Infectious Diseases,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Pokfulam,Hong Kong,China;State Key Laboratory of Veterinary Biotechnology,Harbin Veterinary Research Institute,Chinese Academy of Agricultural Sciences,Harbin,China;CenBRAIN Lab.,School of Engineering,Westlake University,Hangzhou,Zhejiang,China;CenBRAIN Lab.,Westlake Institute for Advanced Study,Hangzhou,Zhejiang,China;School of Biomedical Sciences,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Pokfulam,Hong Kong,China
引用格式:
[1]Mengjiao Li;Zi-Wei Ye;Kaiming Tang;Liang Guo;Wenwen Bi;Yuyuan Zhang;Yan-dong Tang;Guoguang Rong;Mohamad Sawan;Xin Yin;Ren Sun;Shuofeng Yuan;Bobo Dang-.Enhanced trimeric ACE2 exhibits potent prophylactic and therapeutic efficacy against the SARS-CoV-2 Delta and Omicron variants in vivo)[J].细胞研究(英文版),2022(06):589-592
A类:
hesi,tancy,evades
B类:
Enhanced,trimeric,ACE2,exhibits,potent,prophylactic,therapeutic,efficacy,against,SARS,CoV,Delta,Omicron,variants,vivo,Dear,Editor, The,outbreak,coronavirus,disease,has,resulted,severe,global,pandemic,that,lasted,more,than,two,years,Several,vaccines,were,developed,unprecedented,speed,protect,billions,people,Many,monoclonal,antibodies,have,also,been,discovered,several,which,are,clinical,stages,However,limited,availability,compromise,impact,continuous,evolution,many,can,immunity,reducing,effects,With,mutations,spike,protein,escapes,majority,existing,extensively,induced,Thus,tics,broadly,effective,current,future,emerging,still,highly,desirable
AB值:
0.633729
相似文献
An ultrapotent pan-β-coronavirus lineage B(β-CoV-B)neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope
Zezhong Liu;Wei Xu;Zhenguo Chen;Wangjun Fu;Wuqiang Zhan;Yidan Gao;Jie Zhou;Yunjiao Zhou;Jianbo Wu;Qian Wang;Xiang Zhang;Aihua Hao;Wei Wu;Qianqian Zhang;Yarning Li;Kaiyue Fan;Ruihong Chen;Qiaochu Jiang;Christian T.Mayer;Till Schoofs;Youhua Xie;Shibo Jiang;Yumei Wen;Zhenghong Yuan;Kang Wang;Lu Lu;Lei Sun;Qiao Wang-Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS),School of Basic Medical Sciences;Shanghai Institute of Infectious Disease and Biosecurity;the Fifth People's Hospital of Shanghai;Shanghai Key Laboratory of Medical Epigenetics,International Co-laboratory of Medical Epigenetics and Metabolism(Ministry of Science and Technology);Institutes of Biomedical Sciences;Biosafety Level 3 Laboratory,Shanghai Medical College,Fudan University,Shanghai 200032,China;CAS Key Laboratory of Infection and Immunity,National Laboratory of Macromolecules,Institute of Biophysics,Chinese Academy of Sciences,Beijing 100101,China;Experimental Immunology Branch,Center for Cancer Research,National Cancer Institute,National Institutes of Health,Bethesda,MD 20892,USA;GSK Vaccines,1300 Wavre,Belgium
Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants
Jia Lu;Qiangling Yin;Rongjuan Pei;Qiu Zhang;Yuanyuan Qu;Yongbing Pan;Lina Sun;Ding Gao;Cuiqin Liang;Jingwen Yang;Wei Wu;Jiandong Li;Zongqiang Cui;Zejun Wang;Xinguo Li;Dexin Li;Shiwen Wang;Kai Duan;Wuxiang Guan;Mifang Lian;Xiaoming Yang-National Engineering Technology Research Center for Combined Vaccines,Wuhan Institute of Biological Products Co.Ltd.,Wuhan,430070,China;State Key Laboratory for Molecular Virology and Genetic Engineering National Institute for Viral Disease Control and Prevention,Chinese Center for Disease Control and Prevention,Beijing,102206,China;Center for Emerging Infectious Diseases,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan,430071,China;CDC-WIV Joint Research Center for Emerging Diseases and Biosafety,Wuhan,430071,China;Institution of Infectious Diseases,Shenzhen Bay Laboratory,Shenzhen,518107,China
Neutralization of five SARS-CoV-2 variants of concern by convalescent and BBIBP-CorV vaccinee serum
Yuqi Zhu;Xinyi Yang;Jingna Xun;Jun Liu;Qing Wen;Yixiao Lin;Xiaoting Shen;Jun Chen;Songhua Yuan;Xiaying Zhao;Jing Wang;Hanyu Pan;Jinlong Yang;Zhiming Liang;Yue Liang;Qinru Lin;Huitong Liang;Min Li;Jianping Liu;Yinzhong Shen;Xiaoyan Zhang;Pengfei Wang;Daru Lu;Chunhua Yin;Jianqing Xu;Shibo Jiang;Hongzhou Lu;Huanzhang Zhu-State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology,Ministry of Education,Institute of Genetics,School of Life Sciences,Fudan University,Shanghai,200438,China;Scientific Research Center,Shanghai Public Health Clinical Center,Fudan University,Shanghai,201508,China;Fubio(Suzhou)Biomedical Technology Co.,Ltd,Suzou,215300,China;Department of Infectious Diseases and Immunology,Shanghai Public Health Clinical Center,Fudan University,Shanghai,201508,China;Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS),School of Basic Medical Sciences,Fudan University,Shanghai,200032,China;Department of Infectious Diseases and Nursing Research Institution,National Clinical Research Center for Infectious Diseases,The Third People's Hospital of Shenzhen,Shenzhen,518112,China
Early assessment of the safety and immunogenicity of a third dose(booster)of COVID-19 immunization in Chinese adults
Yuntao Zhang;Yunkai Yang;Niu Qiao;Xuewei Wang;Ling Ding;Xiujuan Zhu;Yu Liang;Zibo Han;Feng Liu;Xinxin Zhang;Xiaoming Yang-China National Biotec Group Company Limited,Beijing 100024,China;Shanghai Institute of Hematology,State Key Laboratory of Medical Genomics,National Research Center for Translational Medicine at Shanghai,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Beijing Institute of Biological Products,China National Biotec Group Company Limited,Beijing 100176,China;National Vaccine and Serum Institute,China National Biotec Group Company Limited,Beijing 101111,China;Department of Infectious Diseases,Research Laboratory of Clinical Virology,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。